Batavia Biomanufacturing Plans New Pharma Production Facility in the Netherlands
Part of South Korea’s CJ CheilJedang, Batavia expands manufacturing capacity for vaccines, gene therapies and immunotherapies in Leiden
Batavia Biomanufacturing is establishing a state-of-the-art manufacturing facility at Leiden Bio Science Park in the Netherlands. The biomanufacturing service provider is part of Batavia Biosciences, a member of South Korea-based CJ CheilJedang’s global family of companies. Batavia’s new facility marks an expansion of its presence in the Dutch life sciences & health ecosystem, increasing its capacity to produce vaccines, gene therapy treatments and immunotherapies for clients in Europe. Paired with its existing R&D operations in the Netherlands, Batavia’s clinical and commercial manufacturing services will position the company to provide tailored support to its partners across every stage of the biopharmaceutical lifecycle.
“Batavia Biomanufacturing’s manufacturing capacity is a key enabler of our wider strategy to significantly contribute to easing human suffering from infectious diseases, cancer and rare diseases by leveraging our innovative technologies and in-depth know-how,” said Eize de Boer, General Manager of Batavia Biomanufacturing in Leiden. “With the demand for manufacturing continuing to increase, our new facility will enable us to provide our customers with crucial manufacturing services for the delivery of life-saving medicines.”
Cutting-edge solutions for the biopharma lifecycle
With the official opening planned in the autumn of 2025, Batavia Biomanufacturing aims to play a critical role in producing viral vectors and viral vaccines for a range of clients, from small biotech firms to large pharma companies. Batavia’s new commercial-scale facility in Leiden will enable it to achieve these goals, spanning 12,000 square meters and poised to manufacture up to 200 million finished-dose vaccines annually with six production lines. The site will be equipped with the cutting-edge technologies to scale up clients’ pharmaceutical innovations from initial cell cultures to packaged products ready for shipment. This means the new facility will bring valuable production capacity to the Life Science and Health ecosystem in Leiden and the Netherlands.
Furthermore, Batavia’s new facility in the Netherlands will adhere to high industry standards, including EU Good Manufacturing Practice (Pharmaceutical Inspection Cooperation Scheme) and Biosafety Level 2 containment for genetically (non-)modified organisms as needed.
Tapping into the Dutch innovation ecosystem
Along with these advanced capabilities, Batavia will leverage deep expertise from the Netherlands’ innovation landscape and talent pool to deliver scalable, reliable and cost-effective biomanufacturing solutions to its partners. With its location at Leiden Bio Science Park Batavia will further consolidate its ties to one of the top innovation parks in the country. Batavia will continue to tap into this local ecosystem while strengthening the Dutch biopharma value chain, as the company combines the power of its new commercial manufacturing facility with its nearby R&D site in Leiden.
Strengthening resilience against diseases
Guided by a commitment to operational excellence, Batavia’s services to pharmaceutical partners will support public health in the Netherlands and beyond. In particular, the company will accelerate the development and production of vaccines, gene therapies and immunotherapies that are vital for pandemic preparedness. As Batavia increases manufacturing capacity for these medicines, the company directly contributes to the Netherlands’ disease resilience and helps with fighting future outbreaks.
Source: Batavia
26 March 2025